Supplemental Online Content

This supplemental material has been provided by the authors to give readers additional information about their work.

eTable 1: Use of imaging techniques in men with *de novo* mCSPC in 2013-2020 in the National Prostate Cancer Register (NPCR) of Sweden.

	2013 (N=949)	2014 (N=992)	2015 (N=1012)	2016 (N=991)	2017 (N=980)	2018 (N=1025)	2019 (N=1046)	2020 (N=922)
Bone scan[1]	645 (68%)	714 (72%)	739 (73%)	746 (75%)	756 (77%)	763 (74%)	798 (76%)	674 (73%)
CT[1]	112 (12%)	96 (10%)	81 (8%)	129 (13%)	124 (13%)	125 (12%)	123 (12%)	120 (13%)
MR[1]	47 (5%)	36 (4%)	39 (4%)	26 (3%)	30 (3%)	34 (3%)	24 (2%)	35 (4%)
PET-CT[2]	-	14 (1%)	25 (2%)	30 (3%)	37 (4%)	37 (4%)	46 (4%)	61 (7%)
RX[3]	-	-	8 (1%)	4 (0%)	1 (0%)	3 (0%)	2 (0%)	2 (0%)
Unknown	145 (15%)	132 (13%)	120 (12%)	56 (6%)	32 (3%)	63 (6%)	53 (5%)	30 (3%)

[1]Reported in NPCR since January 2013
[2]Reported in NPCR since June 2014
[3]Reported in NPCR since March 2015
CT= computed tomography; MRI=magnetic resonance imaging; PET-CT=positron emission tomography-CT; RX=X-ray imaging.

eTable 2. Five-year crude survival in Kaplan-Meier analysis and standardized survival in parametric models.

| Age			Crude survival in Kaplan-Meier analysis			Standardized survival in parametric models		
			2008–2012	2013–2016	2017–2020	2008–2012	2013–2016	2017–2020
All ages								
	OS	Estimate	26	32	35	27	31	37
		95% CI	(25-28)	(30-33)	(31-40)	(26-28)	(30-32)	(36-39)
	CSS	Estimate	35	42	48	35	39	45
		95% CI	(33-36)	(40-43)	(45-51)	(33-36)	(38-41)	(43-47)
<65 years								
	OS	Estimate	35	45	50	36	42	47
		95% CI	(31-39)	(41-49)	(43-58)	(32-40)	(38-46)	(42-53)
	CSS	Estimate	39	49	55	40	46	52
		95% CI	(35-43)	(45-54)	(48-64)	(35-44)	(42-50)	(46-59)
65–74 years								
	OS	Estimate	34	39	51	34	38	49
		95% CI	(32-37)	(36-41)	(46-55)	(32-37)	(36-40)	(46-52)
	CSS	Estimate	41	46	58	41	45	55
		95% CI	(39-45)	(44-49)	(54-63)	(38-43)	(42-47)	(52-59)
75–79 years								
	OS	Estimate	25	31	34	27	31	37
		95% CI	(22-29)	(28-35)	(27-41)	(25-31)	(28-34)	(33-40)
	CSS	Estimate	35	41	48	37	39	45
		95% CI	(31-39)	(37-45)	(42-54)	(33-41)	(36-43)	(41-50)
> 80 years								
	OS	Estimate	13	17	11	15	19	20
		95% CI	(12-16)	(15-19)	(5-26)	(13-17)	(17-21)	(17-23)
	CSS	Estimate	23	30	28	26	31	30
		95% CI	(20-26)	(27-34)	(21-36)	(23-29)	(28-33)	(27-34)

OS=overall survival; CSS=cause-specific survival; CI=confidence interval

eFigure 1. Median and lower quartile level of PSA for men with *de novo* mCSPC in 2008-2020.

Legend: Solid lines represent median and dashed lines represent lower quartile. PSA=prostate specific antigen

eFigure 2. Unadjusted five-year overall survival for men with *de novo* mCSPC diagnosed in 2008-2020.

Legend: Overall survival calculated by use of Kaplan-Meier estimator. Survival estimates and 95% confidence intervals are reported in eTable 1.